Indoco Remedies Ltd

Indoco Remedies, a small-cap pharmaceutical company, has reached a new 52-week low, continuing a downward trend for the second consecutive day. Over the past year, the stock has declined significantly, contrasting with the overall market's gains, and is currently trading below key moving averages, indicating ongoing challenges.

Indoco Remedies, a small-cap pharmaceutical company, has reached a new 52-week low, reflecting significant underperformance compared to its sector. The stock has seen a 14.74% decline over the past week and has recorded a 33.66% drop over the past year, amidst high volatility in trading.

Indoco Remedies has experienced notable trading activity, gaining 7.1% on February 5, 2025, and outperforming its sector. The stock has risen for five consecutive days, accumulating a total return of 12.56%. Despite recent gains, it remains below several long-term moving averages and has faced a decline over the past month.

Indoco Remedies has experienced notable trading activity, gaining 7.1% on February 5, 2025, and outperforming its sector. The stock has risen for five consecutive days, accumulating a total return of 12.56%. Despite recent gains, it remains below several long-term moving averages and has faced a decline over the past month.

Indoco Remedies, a small-cap pharmaceutical company, is nearing a 52-week low, with its stock showing weak performance today and underperforming its sector. The stock has traded within a narrow range and remains below its moving averages. Over the past year, it has declined significantly compared to the Sensex.

Indoco Remedies, a small-cap pharmaceutical company, has reached a new 52-week low amid significant volatility. The stock has underperformed its sector and is down over 30% in the past year, contrasting with the Sensex's gains. It currently trades below multiple moving averages, indicating a bearish trend.

Indoco Remedies, a small-cap pharmaceutical company, has hit a new 52-week low amid significant volatility, trailing its sector. The stock has seen a 20.8% decline over the past four days and is currently underperforming compared to broader market indices, reflecting ongoing challenges in its performance.

Indoco Remedies has faced significant stock volatility, hitting a new 52-week low and experiencing a consecutive decline over four days, totaling 20.8%. The stock is trading below all major moving averages, reflecting a bearish trend, and has underperformed compared to the broader market indices.

Indoco Remedies has reached a new 52-week low, with its stock price declining significantly over the past year. The company has underperformed its sector and is currently trading below multiple moving averages, highlighting ongoing challenges in the competitive pharmaceuticals market. High volatility has also been noted in recent trading sessions.

Indoco Remedies experienced a significant drop in its stock price on January 22, 2025, underperforming compared to its sector. The stock is trading below multiple moving averages, indicating a bearish trend, and has declined over the past month, contrasting sharply with the benchmark Sensex's performance.

Indoco Remedies has released its financial results for Q3 FY24-25, revealing significant declines in key metrics. The company reported a low operating profit to interest ratio, negative profit before tax and profit after tax, and a decrease in net sales, indicating a challenging financial period.

Indoco Remedies has experienced a notable adjustment in its evaluation, reflecting its recent stock performance. The company, a smallcap player in the pharmaceutical sector, has been added to MarketsMOJO's list, highlighting its potential amidst a positive trend in stock price and strong market outperformance. Investors are advised to monitor future developments closely.

Indoco Remedies, a smallcap pharmaceutical company, saw a significant increase in its stock price on November 22, 2024. The stock gained 8.18%, outperforming the sector by 7.08%. This comes after four consecutive days of decline, indicating a possible trend reversal. The stock is currently trading higher than its 5-day and 20-day moving averages, but lower than its 50-day, 100-day, and 200-day moving averages. Indoco Remedies has also outperformed the Sensex in the past day and month, showing a positive trend for the company's stock.

Indoco Remedies, a smallcap pharmaceutical company, has been downgraded to 'Sell' by MarketsMOJO due to its negative financial performance in the last quarter, with a decline in net sales by -5.03%. The company has consistently reported negative results for the past 8 quarters and has a low operating profit to interest ratio. Technical factors also indicate a bearish trend for the stock. However, the company has a strong ability to service debt and has shown healthy long-term growth. The majority shareholders are the promoters themselves, but the stock has been downgraded due to its declining profits.

Indoco Remedies, a pharmaceutical and drugs company, reported a -31 score for the quarter ending September 2024, a decrease from the previous quarter. Key areas contributing to this decline include a weakening ability to manage interest payments and a decrease in profit before and after tax. Despite these challenges, the company remains a strong player in the smallcap industry with a respectable operating profit margin and potential for future growth.

Indoco Remedies, a smallcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO due to its strong ability to service debt, healthy long-term growth, and bullish technical trend. However, the company has declared negative results for 7 consecutive quarters and has underperformed the market in the past year. Investors should carefully consider all factors before making any investment decisions.